Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Kala BIO, Inc.KALA · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandunder $12.5M assetstotal assets $9.5M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, short runway, late filer, thin data, degenerate inputs · fortress balance sheet
Inputs computable6 of 14
Graded fromfilings received through Apr 15, 2026177 days before the rescan; every figure keyed to the SEC receipt date
Last close$0.302026-10-08; market equity $5.7M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$50NovDecJanFebMarAprMayJunJulAugSepOct$0.30
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2018nonen/aQ2
Mar 21, 2019nonen/aQ3
Mar 21, 2023E99.6Q2
Apr 21, 2024nonen/aQ2
Apr 21, 2026nonen/aQ1

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Apr 15, 2026; the document on sec.gov.

In this Annual Report on Form 10-K, unless the context otherwise requires, references to “we,” “us,” “our,” “our company,” “KALA,” “KALA BIO” and “Company” refer to KALA BIO, Inc. and its subsidiaries. We are a biopharmaceutical company in transition, evaluating the development of a dedicated, on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry. Our current focus is leveraging our mesenchymal stem cell secretome (“MSC-S”) platform to test development of a scalable AI platform-as-a-service business to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 14305.4%[3-4]
Short runway. cash runway is 0.1 months[5]
Late filer. found 3 NT 10-K/Q filings in the last eight quarters
Thin data. 6 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]
Fortress balance sheet. cash minus debt is 27,192,000 USD; Altman Z is not used[6-7]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 94.0
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio15.4%[1,8-10](6.6%)94.08112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 76.9
Twelve-month failure probability0.51%0.07%83.82482026-06-30
Altman Z double-prime(258.66)[1,11-16](0.31)98.87562025-12-31
Net debt to EBITDAnot computable1.82x
EBITDA must exceed $100,000
Interest coveragenot computable(4.51x)
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio3.81x[11-12]2.96x48.08392025-12-31
Growth and financing, sleeve percentile 98.9
Revenue growth, three-year compoundnot computable10.0%
current value must be positive and the base must exceed $100,000
Free cash flow growth, three-year compoundnot computable10.9%
four consecutive annual FCF observations are required; found 3
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three years(52.2%)[1,10,17-18]2.1%98.37042025-12-31
Net share issuance, one year14,305.4%[3-4]2.5%99.56342026-04-10

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(99.1%)8.0%0hotter than 0 of 100 peers
Distance from 52-week high(99.6%)(31.4%)0closer to its high than 0 of 100 peers
EBIT to enterprise value(120.7%)(1.5%)5pricier than 95 of 100 peers
Free cash flow yield(1,639.7%)(1.0%)0pricier than 100 of 100 peers
Book value to price1.580.2894pricier than 6 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five years666.6%20.3%99more equity-funded than 99 of 100 peers
Relative strength against the sector, log excess return(4.95)(0.14)0ahead of 0 of 100 peers

Inputs: market equity $5.7M; EBIT -$39.2M; free cash flow -$94.1M; book equity $9.0M; sales $0; debt $26.9M; cash $229,000[19].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(48.6%)✗ fail[8,10]
Operating cash flow above zero-$32.0M✗ fail[9]
Return on assets improved20.2 pts✓ pass[8,10,17,20]
Operating cash flow exceeds net income-$5.0M✗ fail[8-9]
Long-term leverage felln/a[1,10,17,21]
Current ratio improved69.1 pts✓ pass[11-12,22-23]
No new shares issued14,305.4%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improved0.0 pts✗ fail[2,10,17,24]
Cash, filings, liquidity
Cash and equivalents$229,000[5]
Operating cash flow, four quarters-$19.9M[5,9,25-28]
Months of runway0.1
Late filings, two years3
NT 10-K or NT 10-Q
Days since last periodic filing51
10-Q received Aug 19, 2026
Median daily dollar volume$90,415
63 sessions
Days since newest grade input177

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$9.5M2025-12-312026-04-1510-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax$02025-12-312026-04-1510-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding929,491,5782026-04-102026-04-1510-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding6,452,3982025-03-282025-03-3110-Kfiling · viewer · series
5cashus-gaap:CashAndCashEquivalentsAtCarryingValue$229,0002026-06-302026-08-1910-Qfiling · viewer · series
6cashus-gaap:CashAndCashEquivalentsAtCarryingValue$70.5M2022-12-312024-03-2910-Kfiling · viewer · series
7total debtus-gaap:LongTermDebt$43.3M2022-12-312023-03-0310-Kfiling · viewer · series
8net incomeus-gaap:NetIncomeLoss-$27.0M2025-12-312026-04-1510-Kfiling · viewer · series
9operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$32.0M2025-12-312026-04-1510-Kfiling · viewer · series
10assetsus-gaap:Assets$55.5M2024-12-312026-04-1510-Kfiling · viewer · series
11current assetsus-gaap:AssetsCurrent$9.5M2025-12-312026-04-1510-Kfiling · viewer · series
12current liabilitiesus-gaap:LiabilitiesCurrent$2.5M2025-12-312026-04-1510-Kfiling · viewer · series
13retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$694.9M2025-12-312026-04-1510-Kfiling · viewer · series
14operating incomeus-gaap:OperatingIncomeLoss-$39.2M2025-12-312026-04-1510-Kfiling · viewer · series
15book equityus-gaap:StockholdersEquity$7.0M2025-12-312026-04-1510-Kfiling · viewer · series
16liabilitiesus-gaap:Liabilities$2.5M2025-12-312026-04-1510-Kfiling · viewer · series
17assetsus-gaap:Assets$55.9M2023-12-312025-03-3110-Kfiling · viewer · series
18assetsus-gaap:Assets$86.8M2022-12-312024-03-2910-Kfiling · viewer · series
19shares outstandingdei:EntityCommonStockSharesOutstanding19,339,7862026-08-142026-08-1910-Qfiling · viewer · series
20net incomeus-gaap:NetIncomeLoss-$38.5M2024-12-312026-04-1510-Kfiling · viewer · series
21long term debtus-gaap:LongTermDebtNoncurrent$20.1M2024-12-312026-04-1510-Kfiling · viewer · series
22current assetsus-gaap:AssetsCurrent$52.8M2024-12-312026-04-1510-Kfiling · viewer · series
23current liabilitiesus-gaap:LiabilitiesCurrent$17.0M2024-12-312026-04-1510-Kfiling · viewer · series
24revenueus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax$02024-12-312026-04-1510-Kfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$4.4M2026-06-302026-08-1910-Qfiling · viewer · series
26operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$2.9M2026-03-312026-05-1510-Qfiling · viewer · series
27operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$27.4M2025-09-302025-11-1910-Qfiling · viewer · series
28operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$16.6M2025-06-302026-08-1910-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.